Enhanced hydrocarbon recovery by permeability modification with phenolic
gels
    2.
    发明授权
    Enhanced hydrocarbon recovery by permeability modification with phenolic gels 失效
    通过酚醛凝胶的渗透性改性提高烃回收率

    公开(公告)号:US4708974A

    公开(公告)日:1987-11-24

    申请号:US656801

    申请日:1984-10-01

    CPC分类号: C09K8/885 E21B43/32

    摘要: Hydrocarbon recovery from subterranean reservoirs that are penetrated by either injector or producer wells is enhanced by selective permeability modification of the strata of the reservoir with gel-forming phenolic compositions. The injection of the phenolic composition follows a pH sequence specific to the reservoir environment which allows emplacement of the gel-forming composition the desired distance away from the wellbore and production of a uniform gel throughout the treated hydrocarbon-bearing reservoir. The permeability of a treated subterranean reservoir can be restored by treatment of the reservoir with either aqueous hypochlorite or mineral acid.

    摘要翻译: 通过用凝胶形成酚类组合物对储层的层的选择性渗透性改性来增强由注入井或生产井渗透的地下储层的烃回收。 酚类组合物的注入遵循对储层环境特异性的pH序列,其允许将凝胶形成组合物置于远离井筒的期望距离并在整个经处理的含烃储层中产生均匀的凝胶。 经处理的地下储层的渗透性可以通过用次氯酸盐水溶液或无机酸处理储层来恢复。

    Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one and salts thereof, useful in the treatment of cancer
    3.
    发明授权
    Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one and salts thereof, useful in the treatment of cancer 失效
    6 - [(4-氯 - 苯基) - 羟基 - (3-甲基-3H-咪唑-4-基) - 甲基] -4- [3-(3-羟基-3-甲基 - 苯基] - 苯基] -1-甲基-1H-喹啉-2-酮及其盐,其可用于治疗癌症

    公开(公告)号:US07176315B2

    公开(公告)日:2007-02-13

    申请号:US10824034

    申请日:2004-04-14

    IPC分类号: C07D215/16

    CPC分类号: C07D401/06

    摘要: This invention relates to the enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one, prodrugs thereof, and pharmaceutically acceptable salts and solvates of said compounds and said prodrugs, that are useful in the treatment of hyperproliferative diseases, such as cancers, in mammals. The invention also relates to processes for the production of enantiomerically pure or optically enriched (+)- or (−)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one enantiomers from a mixture containing two enantiomers using continuous chromatography. The invention further relates to the L-(+)-tartaric acid or (S)-(−)-1,1′-binapthyl-2,2′-diyl hydrogenphosphate salts of (+)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one.

    摘要翻译: 本发明涉及6 - [(4-氯 - 苯基) - 羟基 - (3-甲基-3H-咪唑-4-基) - 甲基] -4- [3-(3-羟基-3-甲基 - 丁-1-炔基) - 苯基] -1-甲基-1H-喹啉-2-酮,其前药和所述化合物和所述前药的药学上可接受的盐和溶剂化物,其可用于治疗过度增殖性疾病,例如 作为癌症,在哺乳动物。 本发明还涉及制备对映体纯的或光学富集的(+) - 或( - ) - 6 - [(4-氯 - 苯基) - 羟基 - (3-甲基-3H-咪唑-4-基) - 甲基] -4- [3-(3-羟基-3-甲基 - 异-1-炔基) - 苯基] -1-甲基-1H-喹啉-2-酮对映异构体。 本发明还涉及(+) - 6 - [(4-氯) - (+) - 酒石酸或(S) - ( - ) - 1,1'-二萘基-2,2'-二基磷酸氢盐 - 苯基) - 羟基 - (3-甲基-3H-咪唑-4-基) - 甲基] -4- [3-(3-羟基-3-甲基 - 丁-1-炔基) - 苯基] -1-甲基 -1H-喹啉-2-酮。

    ENANTIOMERS OF 6-[(4-CHLORO-PHENYL)-HYDROXY-(3-METHYL-3H-IMIDAZOL-4-YL)-METHYL]-4-[3-(3-HYDROXY-3-METHYL-BUT-1-YNYL)-PHENYL]-1-METHYL-1H-QUINOLIN-2-ONE AND SALTS THEREOF, USEFUL IN THE TREATMENT OF CANCER
    6.
    发明授权
    ENANTIOMERS OF 6-[(4-CHLORO-PHENYL)-HYDROXY-(3-METHYL-3H-IMIDAZOL-4-YL)-METHYL]-4-[3-(3-HYDROXY-3-METHYL-BUT-1-YNYL)-PHENYL]-1-METHYL-1H-QUINOLIN-2-ONE AND SALTS THEREOF, USEFUL IN THE TREATMENT OF CANCER 失效
    6 - [(4-氯苯基) - 羟基 - (3-甲基-3H-咪唑-4-基) - 甲基] -4- [3-(3-羟基-3-甲基 - YNYL) - 苯基] -1-甲基-1H-喹啉-2-酮及其盐,用于治疗癌症

    公开(公告)号:US06740757B2

    公开(公告)日:2004-05-25

    申请号:US10228657

    申请日:2002-08-27

    IPC分类号: A61K3147

    CPC分类号: C07D401/06

    摘要: This invention relates to the enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one, prodrugs thereof, and pharmaceutically acceptable salts and solvates of said compounds and said prodrugs, that are useful in the treatment of hyperproliferative diseases, such as cancers, in mammals. The invention also relates to processes for the production of enantiomerically pure or optically enriched (+)- or (−)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one enantiomers from a mixture containing two enantiomers using continuous chromatography. The invention further relates to the L-(+)-tartaric acid or (S)-(−)-1,1′-binapthyl-2,2′-diyl hydrogenphosphate salts of (+)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one.

    摘要翻译: 本发明涉及6 - [(4-氯 - 苯基) - 羟基 - (3-甲基-3H-咪唑-4-基) - 甲基] -4- [3-(3-羟基-3-甲基 - 丁-1-炔基) - 苯基] -1-甲基-1H-喹啉-2-酮,其前药和所述化合物和所述前药的药学上可接受的盐和溶剂化物,其可用于治疗过度增殖性疾病,例如 作为癌症,在哺乳动物。 本发明还涉及制备对映体纯的或光学富集的(+) - 或( - ) - 6 - [(4-氯 - 苯基) - 羟基 - (3-甲基-3H-咪唑-4-基) - 甲基] -4- [3-(3-羟基-3-甲基 - 异-1-炔基) - 苯基] -1-甲基-1H-喹啉-2-酮对映异构体。 本发明还涉及(+) - 6 - [(4-氯) - (+) - 酒石酸或(S) - ( - ) - 1,1'-二萘基-2,2'-二基磷酸氢盐 - 苯基) - 羟基 - (3-甲基-3H-咪唑-4-基) - 甲基] -4- [3-(3-羟基-3-甲基 - 丁-1-炔基) - 苯基] -1-甲基 -1H-喹啉-2-酮。

    Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one and salts thereof, useful in the treatment of cancer
    9.
    发明申请
    Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one and salts thereof, useful in the treatment of cancer 审中-公开
    6 - [(4-氯 - 苯基) - 羟基 - (3-甲基-3H-咪唑-4-基) - 甲基] -4- [3-(3-羟基-3-甲基 - 苯基] - 苯基] -1-甲基-1H-喹啉-2-酮及其盐,其可用于治疗癌症

    公开(公告)号:US20110097315A1

    公开(公告)日:2011-04-28

    申请号:US11705557

    申请日:2007-02-12

    CPC分类号: C07D401/06

    摘要: This invention relates to the enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-43-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one, prodrugs thereof, and pharmaceutically acceptable salts and solvates of said compounds and said prodrugs, that are useful in the treatment of hyperproliferative diseases, such as cancers, in mammals. The invention also relates to processes for the production of enantiomerically pure or optically enriched (+)- or (−)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one enantiomers from a mixture containing two enantiomers using continuous chromatography. The invention further relates to the L-(+)-tartaric acid or (S)-(−)-1,1′-binapthyl-2,2′-diyl hydrogenphosphate salts of (+)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one.

    摘要翻译: 本发明涉及6 - [(4-氯 - 苯基) - 羟基 - (3-甲基-3H-咪唑-4-基) - 甲基] -4- [3-(3-羟基-3-甲基 - 丁-1-炔基) - 苯基] -1-甲基-1H-喹啉-2-酮,其前药和所述化合物和所述前药的药学上可接受的盐和溶剂化物,其可用于治疗过度增殖性疾病,例如 作为癌症,在哺乳动物。 本发明还涉及制备对映体纯的或光学富集的(+) - 或( - ) - 6 - [(4-氯 - 苯基) - 羟基 - (3-甲基-3H-咪唑-4-基) - 甲基] -4- [3-(3-羟基-3-甲基 - 异-1-炔基) - 苯基] -1-甲基-1H-喹啉-2-酮对映异构体。 本发明还涉及(+) - 6 - [(4-氯) - (+) - 酒石酸或(S) - ( - ) - 1,1'-二萘基-2,2'-二基磷酸氢盐 - 苯基) - 羟基 - (3-甲基-3H-咪唑-4-基) - 甲基] -4- [3-(3-羟基-3-甲基 - 丁-1-炔基) - 苯基] -1-甲基 -1H-喹啉-2-酮。